Deal Announcements

CytomX Lands New Venture Capital Investment

Friday, September 24, 2010 5:56:00 AM PDT | VentureDeal Staff

Santa Barbara, California  --  Biotechnology company CytomX Therapeutics has secured $30 million in new venture capital and strategic investment.

CytomX is developing what it calls "Probodies", which are proteolytically-activated antibodies.

Third Rock Ventures led the round, which also included the Roche Venture Fund. The company said it would use the financing proceeds to advance its anti-body platform and to move the company to the bay area by the end of this year.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1